A 42.5% absolute improvement in HiSCR75 response rate at Week 16 — against a placebo rate of 25.6% — is not a modest signal in hidradenitis suppurativa. It is the highest absolute HiSCR75 improvement reported in any similarly sized or larger HS trial at either individual dose or combined, which positions abdakibart’s Phase 2 LOTUS readout as a genuine benchmark rather than a incremental step forward in a disease where most IL-17 and TNF inhibitors plateau well short of that threshold.
The design detail that matters most here is the dual-dose structure: 150 mg and 300 mg both cleared the primary endpoint with p-values of 0.018 and 0.015 respectively, while the combined analysis reached p=0.004. That consistency across doses does two things for Phase 3 planning. It removes the usual dose-selection uncertainty that forces sponsors into adaptive designs or requires costly additional arms, and it gives Avalo a clean argument for a monthly dosing regimen — a meaningful differentiator in HS, where biweekly injections remain the standard and adherence is a chronic problem. Statistical significance on key secondary endpoints including IHS4 and draining tunnel count further tightens the efficacy narrative across dimensions that regulators and clinicians actually use to assess disease burden.
The financing context changes Avalo’s strategic position dramatically. The company closed a $431.3 million public offering on May 7, converting a balance sheet that showed just $82 million in cash as of March 31 into a runway explicitly projected through 2029. That capital buffer is not just operational comfort — it is the difference between a company that negotiates from desperation and one that can design a properly powered, multi-regional Phase 3 without compromising on sample size or endpoint selection. Equally notable is the AlmataBio milestone restructuring: paying $2.25 million now for an option to settle a $15 million Phase 3 trigger obligation at $5.125 million is a $7.6 million reduction in contingent liability, executed quietly before the financing closed. That is disciplined cap-table management, not coincidence.
The single marker to track as Phase 3 design emerges is whether Avalo pursues HiSCR75 as the primary registrational endpoint or defaults to HiSCR50. Choosing HiSCR75 would be a deliberate bet on differentiation — and given the LOTUS data, it is a bet they can now credibly make.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
